Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Urogenital Neoplasms 1Prostatic Neoplasms 1Neoplasms by Site 1Genital Neoplasms, Male 1Genital Diseases, Male 1Breast Neoplasms 1

Interventions

Mitomycin 3Abiraterone Acetate 3motexafin gadolinium 2abiraterone 2Suspensions 2Sunitinib 2Powders 2Paclitaxel 2Gemcitabine 2Drug Therapy 2Docetaxel 2vinflunine 1valrubicin 1temsirolimus 1sipuleucel-T 1pembrolizumab 1palbociclib 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1atezolizumab 1apalutamide 1abemaciclib 1Watchful Waiting 1Transurethral Resection of Prostate 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urogenital Neoplasms × BAY 86-7548 × Clear all
NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Lantheus Biosciences Ltd.

Phase 1/2 Terminated
30 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡